CA2687380A1 - New pharmaceutical compositions comprising diiodothyronine and their therapeutic use - Google Patents

New pharmaceutical compositions comprising diiodothyronine and their therapeutic use Download PDF

Info

Publication number
CA2687380A1
CA2687380A1 CA002687380A CA2687380A CA2687380A1 CA 2687380 A1 CA2687380 A1 CA 2687380A1 CA 002687380 A CA002687380 A CA 002687380A CA 2687380 A CA2687380 A CA 2687380A CA 2687380 A1 CA2687380 A1 CA 2687380A1
Authority
CA
Canada
Prior art keywords
day
diiodothyronine
iodothyronine
active substance
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002687380A
Other languages
English (en)
French (fr)
Inventor
Xavier Leverve
Nellie Taleux
Roland Favier (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Joseph Fourier University
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2687380A1 publication Critical patent/CA2687380A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002687380A 2007-05-16 2008-05-16 New pharmaceutical compositions comprising diiodothyronine and their therapeutic use Abandoned CA2687380A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290634.0 2007-05-16
EP07290634 2007-05-16
PCT/EP2008/056074 WO2008138993A1 (en) 2007-05-16 2008-05-16 New pharmaceutical compositions comprising diiodothyronine and their therapeutic use

Publications (1)

Publication Number Publication Date
CA2687380A1 true CA2687380A1 (en) 2008-11-20

Family

ID=38521888

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002687380A Abandoned CA2687380A1 (en) 2007-05-16 2008-05-16 New pharmaceutical compositions comprising diiodothyronine and their therapeutic use

Country Status (5)

Country Link
US (1) US20110028554A1 (enExample)
EP (1) EP2068858A1 (enExample)
JP (1) JP2010526857A (enExample)
CA (1) CA2687380A1 (enExample)
WO (1) WO2008138993A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992341A1 (en) * 2007-05-16 2008-11-19 Université Joseph Fourier New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
US20120065267A1 (en) * 2010-09-09 2012-03-15 T*Amine, Llc Compositions including 3,5-l-t2 and methods of use thereof
JP6352188B2 (ja) 2012-08-20 2018-07-04 大塚製薬株式会社 糖代謝能の測定方法及びそれに使用する組成物
KR20210014204A (ko) * 2013-03-15 2021-02-08 오츠카 세이야쿠 가부시키가이샤 지방산 연소에 의한 인슐린 저항성의 측정 방법, 및 그에 사용하는 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067247A (en) * 1958-08-19 1962-12-04 Hoechst Ag Process for preparing l(+)-3, 5-diiodothyronine
US4426453A (en) * 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
US5767227A (en) * 1989-11-03 1998-06-16 Lotus Biochemical Corp. Iodothyronine polymers
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
US5635209A (en) * 1995-10-31 1997-06-03 Vintage Pharmaceuticals, Inc. Stabilized composition of levothyroxine sodium medication and method for its production
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.

Also Published As

Publication number Publication date
US20110028554A1 (en) 2011-02-03
EP2068858A1 (en) 2009-06-17
WO2008138993A1 (en) 2008-11-20
JP2010526857A (ja) 2010-08-05

Similar Documents

Publication Publication Date Title
Owen et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
Wilson Regulation of vitamin C transport
KR100533618B1 (ko) 당뇨병 치료를 위한 방법 및 조성물
Lane et al. 2-Deoxy-D-glucose feeding in rats mimics physiologic effects of calorie restriction
Leclercq et al. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARγ agonist pioglitazone
Vallon et al. Renal tubular handling of glucose and fructose in health and disease
Yang et al. Insulin stimulates Akt translocation to mitochondria: implications on dysregulation of mitochondrial oxidative phosphorylation in diabetic myocardium
US10137099B2 (en) Activation of AMP-protein activated kinase by oxaloacetate compounds
EP1992341A1 (en) New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
Papazoglou et al. Hypothalamic serotonin–insulin signaling cross-talk and alterations in a type 2 diabetic model
Fiedler et al. 5-aminoimidazole-4-carboxy-amide-1-β-D-ribofuranoside treatment ameliorates hyperglycaemia and hyperinsulinaemia but not dyslipidaemia in KKAy-CETP mice
Tessari Changes in protein, carbohydrate, and fat metabolism with aging: possible role of insulin
Latham et al. Neuroprotective effects of carnitine and its potential application to ameliorate neurotoxicity
WO2005009433A1 (en) Use of 3,5 diiodothyronine as regulators of lipid metabolism
US20110028554A1 (en) pharmaceutical compositions comprising diiodothyronine and their therapeutic use
US9629896B2 (en) Composition including the HIP/PAP protein or one of the derivatives thereof for treating insulin resistance
Stevenson et al. The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high-fat diet
WO2014066830A1 (en) Composition and methods for the prevention and treatment of diet-induced obesity
CN116801733A (zh) 用于在慢性炎症性病症中靶向晚期糖基化终产物受体(rage)的组合物
KR20030016228A (ko) 신경펩티드 ｙ 농도의 감소에 의해 유도되는 체중 감량
Jubouri The effects of alanine on glucose metabolism in rainbow trout: Integration of glucose fluxes and molecular evidence
Hwang et al. Different roles of zinc plus arachidonic acid on insulin sensitivity between high fructose-and high fat-fed rats
JP2004215562A (ja) 飲食物用添加剤、医薬組成物、ｇｌｕｔ４トランスロケート剤及びトランスロケート方法
WINARSI et al. Soy germed protein plus Zn as an inducer insulin secretion on Type-2 Diabetes Mellitus
ES2972498T3 (es) Composición y método para la prevención y tratamiento de la diabetes tipo 2

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140516